Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Cullinan

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Biochemical and Biophysical Research Communications|July 16, 1996
Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2A Elbrecht, Y Chen, C A Cullinan, et al.
Ultrasound in Medicine & Biology|January 1, 1995
Serial assessment of adnexal masses with transvaginal color Doppler sonographyA C Fleischer, J A Cullinan, H W Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1987
Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanomaR F Morton, E T Creagan, S A Cullinan, et al.
Medical and Pediatric Oncology|January 1, 1988
Phase II study of bisantrene administered by continuous 72-hour infusion for advanced pancreatic adenocarcinomaR F Marschke, L K Kvols, S A Cullinan, et al.
Cancer Treatment Reports|August 1, 1986
Ineffectiveness of tamoxifen in advanced endometrial carcinoma after failure of progestin treatmentJ H Edmonson, J E Krook, J F Hilton, et al.
Cancer Treatment Reports|December 1, 1977
Phase II study of cytosine arabinoside in advanced large bowel cancerS A Cullinan, M J O'Connell, C G Moertel, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1994
SNF9007: a novel analgesic that acts simultaneously at delta 1, delta 2 and mu opioid receptorsC L Williams, G C Rosenfeld, N Dafny, et al.
Endocrinology|October 1, 1996
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db miceJ Berger, P Bailey, C Biswas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment GroupS A Cullinan, C G Moertel, H S Wieand, et al.
American Journal of Clinical Oncology|April 1, 1988
Phase II studies of bleomycin, cyclophosphamide, doxorubicin and cisplatin, and bleomycin and cisplatin in advanced cervical carcinomaJ H Edmonson, P S Johnson, H S Wieand, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Biochemical and Biophysical Research Communications|July 16, 1996
Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2A Elbrecht, Y Chen, C A Cullinan, et al.
Ultrasound in Medicine & Biology|January 1, 1995
Serial assessment of adnexal masses with transvaginal color Doppler sonographyA C Fleischer, J A Cullinan, H W Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1987
Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanomaR F Morton, E T Creagan, S A Cullinan, et al.
Medical and Pediatric Oncology|January 1, 1988
Phase II study of bisantrene administered by continuous 72-hour infusion for advanced pancreatic adenocarcinomaR F Marschke, L K Kvols, S A Cullinan, et al.
Cancer Treatment Reports|August 1, 1986
Ineffectiveness of tamoxifen in advanced endometrial carcinoma after failure of progestin treatmentJ H Edmonson, J E Krook, J F Hilton, et al.
Cancer Treatment Reports|December 1, 1977
Phase II study of cytosine arabinoside in advanced large bowel cancerS A Cullinan, M J O'Connell, C G Moertel, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1994
SNF9007: a novel analgesic that acts simultaneously at delta 1, delta 2 and mu opioid receptorsC L Williams, G C Rosenfeld, N Dafny, et al.
Endocrinology|October 1, 1996
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db miceJ Berger, P Bailey, C Biswas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment GroupS A Cullinan, C G Moertel, H S Wieand, et al.
American Journal of Clinical Oncology|April 1, 1988
Phase II studies of bleomycin, cyclophosphamide, doxorubicin and cisplatin, and bleomycin and cisplatin in advanced cervical carcinomaJ H Edmonson, P S Johnson, H S Wieand, et al.
Pageof 7